Max Nisen, Columnist

Biotech Gets More Forgiving, But Riskier

Last year biotech could do no right. Now it can do no wrong.

September 13, 2017 at 2:16 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

1505314172_GettyImages-458176800 — Photographer: Freya Ingrid Morales

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

More than just about any other sector, biotech demands faith from its investors.

Right now, belief appears to be strong. Faced with a string of worrying news from prominent biotechs in the past two weeks, investors have largely been willing to give the benefit of the doubt. That's a big shift from 2016, when any weakness was immediate cause for a huge selloff.